<qa>  What is the risk assessment of patients with prior use of Everolimus or other mTOR6. Patients with prior use of Everolimus or other mTOR inhibitors such as f.e. Rapamycin or any analogue within the last 6 months; regardless of therapeutic effect, but with risk assessment due to former side effects. 